Arthritis

Levolta Pharmaceuticals Partners with Tabuk Pharmaceuticals for Commercialization of Investigational Osteoarthritis Therapy in Middle East and Africa

Retrieved on: 
Thursday, June 1, 2023

BETHLEHEM, Pa., June 1, 2023 /PRNewswire/ -- Levolta Pharmaceuticals , Inc. has entered into an exclusive licensing and distribution agreement for VOLT01 with Tabuk Pharmaceutical Manufacturing Company of Riyadh, Saudi Arabia, for the commercialization of an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region, excluding South Africa.

Key Points: 
  • BETHLEHEM, Pa., June 1, 2023 /PRNewswire/ -- Levolta Pharmaceuticals , Inc. has entered into an exclusive licensing and distribution agreement for VOLT01 with Tabuk Pharmaceutical Manufacturing Company of Riyadh, Saudi Arabia, for the commercialization of an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region, excluding South Africa.
  • Tabuk is the market leader in MEA and will be a valuable partner in fulfilling that mission."
  • Tabuk Pharmaceuticals, a fully owned subsidiary of Astra Industrial Group, will hold the marketing authorization and be responsible for registering, importing, and commercializing VOLT01 in the MEA region.
  • "At Tabuk Pharmaceuticals, we believe in our vital role to provide patients across the Middle East and Africa with unique healthcare solutions that support their wellbeing," said Mohammed Al Hagbani, CEO of Tabuk Pharmaceuticals and President of Astra Industrial Group.

ACADEMY OF NUTRITION AND DIETETICS NAMES NEW NATIONAL MEDIA SPOKESPEOPLE FOR 2023-2026

Retrieved on: 
Thursday, June 1, 2023

CHICAGO, June 01, 2023 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics, the world’s largest organization of food and nutrition professionals, has appointed two registered dietitian nutritionists to three-year terms as media spokespeople and reappointed six spokespeople to another term.

Key Points: 
  • CHICAGO, June 01, 2023 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics, the world’s largest organization of food and nutrition professionals, has appointed two registered dietitian nutritionists to three-year terms as media spokespeople and reappointed six spokespeople to another term.
  • As registered dietitian nutritionists, Academy Spokespeople are the food and nutrition experts .
  • Her areas of expertise include disease prevention, employee wellness, maternal and prenatal nutrition, vegetarian and vegan nutrition and wellness nutrition.
  • Representing more than 112,000 credentialed nutrition and dietetics practitioners, the Academy of Nutrition and Dietetics is the world’s largest organization of food and nutrition professionals.

Feinstein Institutes bioelectronic medicine researchers stimulate vagus nerve to reduce bleeding in hemophilia

Retrieved on: 
Thursday, June 1, 2023

Researchers at The Feinstein Institutes for Medical Research have shown that electrically stimulating the vagus nerve can reduce bleeding in preclinical hemophilic mice models – a finding that could translate into human patients.

Key Points: 
  • Researchers at The Feinstein Institutes for Medical Research have shown that electrically stimulating the vagus nerve can reduce bleeding in preclinical hemophilic mice models – a finding that could translate into human patients.
  • The study, published in Nature Communications , builds on years of research into harnessing the vagus nerve through electrical stimulation, a foundation of bioelectronic medicine.
  • (Feinstein Institutes)
    Led by Jared Huston, MD , associate professor of surgery and science education at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Institute of Bioelectronic Medicine at the Feinstein Institutes, the research shows that vagus nerve stimulation reduces bleeding in hemophilia A mice to the same degree as replacing missing clotting factor – the current gold-standard therapy for patients living with hemophilia.
  • Huston’s new findings indicate it may be possible to stop life-threatening bleeding by stimulating the vagus nerve.”
    The Feinstein Institutes is known as the global scientific home of bioelectronic medicine because of early discoveries in its labs.

Global Analgesics Market Report 2023: Sector is Expected to Reach $67.55 Billion by 2028 at a CAGR of 4.6% - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 1, 2023

The global analgesics market value is projected to grow at a CAGR of 4.6%, during the forecast period of 2023-2028.

Key Points: 
  • The global analgesics market value is projected to grow at a CAGR of 4.6%, during the forecast period of 2023-2028.
  • In 2022, the global analgesics market was valued at US$51.63 billion, and is probable to reach US$67.55 billion by 2028.
  • There are several different types of analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, and local anesthetics.
  • Trends: A major trend gaining pace in analgesics market is use of artificial intelligence in analgesics.

Zylö Receives $294,000 NIH Phase I Grant to Advance its Cutaneous Lupus Program

Retrieved on: 
Wednesday, May 31, 2023

GREENVILLE, SC, May 31, 2023 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a two-year $294,000 Small Business Technology Transfer Research (STTR) grant to: (i) demonstrate that a formulation of N-acylethanolamine (AEA or anandamide) loaded into Zylö’s novel Z-pod delivery system is efficacious (and well tolerated) in a new mouse model of cutaneous lupus developed at Yale University, and (ii) conduct preliminary stability studies to prepare for an eventual investigational new drug (IND) application to the FDA. The grant is sponsored by the NIH’s National Institute of Arthritis and Musculoskeletal/Skin Disease under Award 1R41AR082749.

Key Points: 
  • The grant is sponsored by the NIH’s National Institute of Arthritis and Musculoskeletal/Skin Disease under Award 1R41AR082749.
  • The principal investigator of the project is Andrew Draganski, Ph.D., Zylö’s head of product development.
  • Dr. Werth is one of the world’s foremost authorities on cutaneous lupus.
  • Approximately 500,000 people in the U.S. suffer from cutaneous lupus erythematosus (CLE), with a significant impact on quality of life.

First Ever Study of RA Patient Attitudes on Bloodwork to Predict Future Treatment Presented by CreakyJoints

Retrieved on: 
Wednesday, May 31, 2023

Most patients understood that their doctor ordered laboratory tests to check for active inflammation (85.9%) or assess side effects of medications (81.2%).

Key Points: 
  • Most patients understood that their doctor ordered laboratory tests to check for active inflammation (85.9%) or assess side effects of medications (81.2%).
  • Most feared (91.4%) that their current RA medication would stop working and that they would waste time trying to find (81.7%) an alternative, effective therapy.
  • “This study demonstrates that patients understand the value of bloodwork, even when they may not fully comprehend how to interpret results and apply them to decisions about care and treatment.
  • Moreover, people living with RA worry about the trial and error process of RA treatment, especially if it means wasting time on a new medication that doesn’t work for them.

Global Companion Animal Rehabilitation Services Market Report 2023: Sector is Expected to Reach $1.18 Billion by 2030 at a CAGR of 11.42% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 30, 2023

The global companion animal rehabilitation services market size is expected to reach USD 1.18 Billion by 2030 to expand at a CAGR of 11.42% from 2023 to 2030.

Key Points: 
  • The global companion animal rehabilitation services market size is expected to reach USD 1.18 Billion by 2030 to expand at a CAGR of 11.42% from 2023 to 2030.
  • The major goal of physical rehabilitation in pet cats and dogs is to speed healing, decrease pain or discomfort, and improve their well-being.
  • Dogs and horses involved in sporting activities are widely known to be benefited from rehabilitation services with high patient compliance.
  • North America is expected to dominate the companion animal rehabilitation services market throughout the projected period owing to the region's large pet care expenditure and pet population.

Enhancing Lives with Ease: Activator® Poles Approved by the Arthritis Foundation

Retrieved on: 
Wednesday, May 31, 2023

By visiting their website, people living with arthritis can conveniently access a comprehensive list of certified arthritis-friendly products, including the Activator® Poles.

Key Points: 
  • By visiting their website, people living with arthritis can conveniently access a comprehensive list of certified arthritis-friendly products, including the Activator® Poles.
  • For people with arthritis, even the simplest activities can feel nearly impossible due to chronic pain.
  • This is why an occupational therapist and gerontologist designed the Activator® Poles specifically for rehab and long-term conditions such as arthritis.
  • During the evaluation process, the Activator® Poles underwent rigorous testing with participants living with various types of arthritis.

University of Manchester Study Using uMotif Next-Generation eCOA/ePRO Data Capture App Reveals Significant Ethnic Disparities in Pain Recognition and Management

Retrieved on: 
Wednesday, May 31, 2023

BOSTON and LONDON, May 31, 2023 /PRNewswire-PRWeb/ -- How people identify and report pain varies based on ethnicity, according to a University of Manchester study. The study, in collaboration with uMotif, was based on the novel Manchester Digital Pain Manikin self-reporting app which was used by participants to record their pain.

Key Points: 
  • The study, in collaboration with uMotif , was based on the novel Manchester Digital Pain Manikin self-reporting app which was used by participants to record their pain.
  • Chronic pain, which affects approximately 28 million people in the UK alone, can create a personal and economic burden.
  • It is essential to accurately measure pain, know its causes, and estimate its impact on people's lives.
  • uMotif Co-founder and Chief Design Officer Ben James ( LinkedIn ) said, "It was an honor for the Digital Pain Manikin app to be used in such an important study.

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023

Retrieved on: 
Tuesday, May 30, 2023

THOUSAND OAKS, Calif., May 30, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and an exploratory analysis of cardiometabolic risk factors, which are commonly elevated in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy.

Key Points: 
  • The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy.
  • "Research presented at EULAR sheds new light on psoriatic arthritis and the role of our oral medication Otezla," said Ponda Motsepe-Ditshego, vice president, Global Medical at Amgen.
  • MOSAIC evaluated Otezla's effect on joint inflammation and structural progression of psoriatic arthritis measured by MRI.
  • "The results of this study are encouraging, as they provide important insights about Otezla treatment and its efficacy on both clinical and inflammatory manifestations of psoriatic arthritis."